Cargando…

Cost of illness among patients with diabetic foot ulcer in Turkey

AIM: To evaluate the annual cost of patients with Wagner grade 3-4-5 diabetic foot ulcer (DFU) from the public payer’s perspective in Turkey. METHODS: This study was conducted focused on a time frame of one year from the public payer’s perspective. Cost-of-illness (COI) methodology, which was develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Oksuz, Ergun, Malhan, Simten, Sonmez, Bilge, Numanoglu Tekin, Rukiye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065666/
https://www.ncbi.nlm.nih.gov/pubmed/27795820
http://dx.doi.org/10.4239/wjd.v7.i18.462
_version_ 1782460353815248896
author Oksuz, Ergun
Malhan, Simten
Sonmez, Bilge
Numanoglu Tekin, Rukiye
author_facet Oksuz, Ergun
Malhan, Simten
Sonmez, Bilge
Numanoglu Tekin, Rukiye
author_sort Oksuz, Ergun
collection PubMed
description AIM: To evaluate the annual cost of patients with Wagner grade 3-4-5 diabetic foot ulcer (DFU) from the public payer’s perspective in Turkey. METHODS: This study was conducted focused on a time frame of one year from the public payer’s perspective. Cost-of-illness (COI) methodology, which was developed by the World Health Organization, was used in the generation of cost data. By following a clinical path with the COI method, the main total expenses were reached by multiplying the number of uses of each expense item, the percentage of cases that used them and unit costs. Clinical guidelines and real data specific to Turkey were used in the calculation of the direct costs. Monte Carlo Simulation was used in the study as a sensitivity analysis. RESULTS: The following were calculated in DFU treatment from the public payer’s perspective: The annual average per patient outpatient costs $579.5 (4.1%), imaging test costs $283.2 (2.0%), laboratory test costs $284.8 (2.0%), annual average per patient cost of intervention, rehabilitation and trainings $2291.7 (16.0%), annual average per patient cost of drugs used $2545.8 (17.8%) and annual average per patient cost of medical materials used in DFU treatment $735.0 (5.1%). The average annual per patient cost for hospital admission is $7357.4 (51.5%). The average per patient complication cost for DFU is $210.3 (1.5%). The average annual per patient cost of DFU treatment in Turkey is $14287.70. As a result of the sensitivity analysis, the standard deviation of the analysis was $5706.60 (n = 5000, mean = $14146.8, 95%CI: $13988.6-$14304.9). CONCLUSION: The health expenses per person are $-PPP 1045 in 2014 in Turkey and the average annual per patient cost for DFU is 14-fold of said amount. The total health expense in 2014 in Turkey is $-PPP 80.3 billion and the total DFU cost has a 3% share in the total annual health expenses for Turkey. Hospital costs are the highest component in DFU disease costs. In order to prevent DFU, training of the patients at risk and raising consciousness in patients with diabetes mellitus (DM) will provide benefits in terms of economy. Appropriate and efficient treatment of DM is a health intervention that can prevent complications.
format Online
Article
Text
id pubmed-5065666
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-50656662016-10-28 Cost of illness among patients with diabetic foot ulcer in Turkey Oksuz, Ergun Malhan, Simten Sonmez, Bilge Numanoglu Tekin, Rukiye World J Diabetes Observational Study AIM: To evaluate the annual cost of patients with Wagner grade 3-4-5 diabetic foot ulcer (DFU) from the public payer’s perspective in Turkey. METHODS: This study was conducted focused on a time frame of one year from the public payer’s perspective. Cost-of-illness (COI) methodology, which was developed by the World Health Organization, was used in the generation of cost data. By following a clinical path with the COI method, the main total expenses were reached by multiplying the number of uses of each expense item, the percentage of cases that used them and unit costs. Clinical guidelines and real data specific to Turkey were used in the calculation of the direct costs. Monte Carlo Simulation was used in the study as a sensitivity analysis. RESULTS: The following were calculated in DFU treatment from the public payer’s perspective: The annual average per patient outpatient costs $579.5 (4.1%), imaging test costs $283.2 (2.0%), laboratory test costs $284.8 (2.0%), annual average per patient cost of intervention, rehabilitation and trainings $2291.7 (16.0%), annual average per patient cost of drugs used $2545.8 (17.8%) and annual average per patient cost of medical materials used in DFU treatment $735.0 (5.1%). The average annual per patient cost for hospital admission is $7357.4 (51.5%). The average per patient complication cost for DFU is $210.3 (1.5%). The average annual per patient cost of DFU treatment in Turkey is $14287.70. As a result of the sensitivity analysis, the standard deviation of the analysis was $5706.60 (n = 5000, mean = $14146.8, 95%CI: $13988.6-$14304.9). CONCLUSION: The health expenses per person are $-PPP 1045 in 2014 in Turkey and the average annual per patient cost for DFU is 14-fold of said amount. The total health expense in 2014 in Turkey is $-PPP 80.3 billion and the total DFU cost has a 3% share in the total annual health expenses for Turkey. Hospital costs are the highest component in DFU disease costs. In order to prevent DFU, training of the patients at risk and raising consciousness in patients with diabetes mellitus (DM) will provide benefits in terms of economy. Appropriate and efficient treatment of DM is a health intervention that can prevent complications. Baishideng Publishing Group Inc 2016-10-15 2016-10-15 /pmc/articles/PMC5065666/ /pubmed/27795820 http://dx.doi.org/10.4239/wjd.v7.i18.462 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Observational Study
Oksuz, Ergun
Malhan, Simten
Sonmez, Bilge
Numanoglu Tekin, Rukiye
Cost of illness among patients with diabetic foot ulcer in Turkey
title Cost of illness among patients with diabetic foot ulcer in Turkey
title_full Cost of illness among patients with diabetic foot ulcer in Turkey
title_fullStr Cost of illness among patients with diabetic foot ulcer in Turkey
title_full_unstemmed Cost of illness among patients with diabetic foot ulcer in Turkey
title_short Cost of illness among patients with diabetic foot ulcer in Turkey
title_sort cost of illness among patients with diabetic foot ulcer in turkey
topic Observational Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065666/
https://www.ncbi.nlm.nih.gov/pubmed/27795820
http://dx.doi.org/10.4239/wjd.v7.i18.462
work_keys_str_mv AT oksuzergun costofillnessamongpatientswithdiabeticfootulcerinturkey
AT malhansimten costofillnessamongpatientswithdiabeticfootulcerinturkey
AT sonmezbilge costofillnessamongpatientswithdiabeticfootulcerinturkey
AT numanoglutekinrukiye costofillnessamongpatientswithdiabeticfootulcerinturkey